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Summary Two-dimensional polyacrylamide gel electrophoresis combined with a non-enzymatic sample
preparation technique is useful for analysing clinical tumour material. Using these techniques, we analysed the
relationship between the histopathological findings in primary lung malignancies and the expression of a
number of unidentified polypeptides that were detected in the molecular weight region 20-35 kDa. In this
study 45 cases of primary lung cancer (PLC) (21 cases of adenocarcinoma, ten cases of squamous cell
carcinoma, five cases of large-cell carcinoma, one case of adenosquamous cell carcinoma, five cases of
small-cell carcinoma and three cases of carcinoid tumour) were examined. For reference, a human diploid
fibroblast cell line (WI38) and normal peripheral lymphocytes were used. Sixteen polypeptides were judged to
be associated with histopathological features. These polypeptides seem to be valuable as differentiation
markers. The simultaneous evaluation of these polypeptides and some other proliferation markers (e.g. PCNA,
PCNA 'satellite', Numatin/protein B23 and lamin B) seems to clarify the characteristics of each case of PLC.
Furthermore, it is possible to classify PLC based on the two-dimensional electrophoresis findings, and this
classification of PLC is suggested to reflect the biological features of the tumour more precisely than that
based only on morphology.
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The range of histological appearances of primary lung cancer
is extremely wide, even although most of such tumours
originate in bronchial epithelium. From a therapeutic stand-
point, lung cancer is usually classified into small-cell lung
cancer (SCLC) and non-small-cell lung cancer (NSCLC).
Small-cell lung cancers which contain cytoplasmic dense-core
granules resembling neuroendocrine granules, seem to
originate from Kultschitzky cells. SCLC is characteristic of
both neuroendocrine cells and epithelial cells, and the
biological behaviour of SCLC is different from that of
NSCLC.
NSCLC can be subdivided into squamous cell carcinoma
(SCC), adenocarcinoma (AdC) and large-cell carcinoma
(LCC). SCC derives from basal cells or intermediate cells of
the relatively large bronchi, and is generally preceded by
squamous metaplasia with increasing degree of atypia (Auer
et al., 1982; Nasiell et al., 1982; Hirano et al., 1994). On the
other hand, most AdC appear in the peripheral bronchi. It is
thought that this type of tumour originates directly from
columnar cells, Clara cells or type II alveolar epithelial cells
of the alveolar sac. The other types of AdC, which occur in
relatively large bronchi, seem to derive from mucous cells,
duct epithelial cells, goblet cells or bronchial glands. Unlike
SCC and AdC, LCC does not show any differentiated
characteristics. The cells of LCC are enlarged and sometimes
show multiple nucleoli.
While unequivocal histological classification can be per-
formed in the vast majority of tumours, poorly differentiated
cases are often difficult to classify.
Recently, several multistep models of epithelial carcin-
ogenesis have been postulated. These models suggest that
abnormalities in several kinds of oncogenes and tumour-
suppressor genes play an important part in carcinogenesis
(Fearon and Vogelstein, 1990). In this context we believe that
the investigation of the molecular events which occur during
malignant transformation in bronchial epithelial cells may be
the basis for the development of improved diagnostic
methods and treatment modalities of PLC. We also suggest
that analysis of gene products contributes valuable inform-
ation concerning tumour aggressiveness and treatment sensit-
ivity, since most cellular functions are related to proteins.
We recently reported that two-dimensional polyacrylamide
gel electrophoresis (2-DE) (O'Farrell, 1975) combined with a
non-enzymatic sample preparation technique is useful for
analysing clinical tumour material (Okuzawa et al., 1994;
Franzen et al., 1993). A number ofpolypeptides were overex-
pressed in SCLC compared with NSCLC. However, only a
few polypeptides seem to differ among various types within
the NSCLC group. The molecular weight region in our
previous study was focused to 30-150 kDa by the homo-
geneous 10%T second dimension. Other investigators suggest
that new potential markers may occur in the molecular
weight region 10-20 kDa (e.g. Op18/stathmin and nm23)
(Strahler et al., 1992; Rosengard et al., 1989). Therefore, we
extended the molecular weight range using a 10-13%T linear
gradient. We describe herein some potential markers for
different histological types of PLC localised in the 20-
35 kDa area of 2-DE gel. The possible relationship between
the expression of these polypeptides and histopathological
characteristics is discussed.
Materials and methods
Clinical material
Clinical specimens were obtained from 45 patients with PLC
resected at the Thoracic Surgery Department of the Karol-
inska Hospital and the Department of Surgery of Tokyo
Medical College Hospital.
Two pathologists diagnosed all lung cancer cases indepen-
dently. Only cases in which full agreement was independently
reached were used.
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Non-enzymatic extractionfrom the clinical materials
Details of this technique have been described previously
(Franzen et al., 1993). Briefly, a resected tumour was cut in
the middle and the fresh surface was scraped with a scalpel
(Figure 1). The cell-rich material was transferred to ice-cold
cell culture medium containing 5% fetal calf serum and
protease inhibitors [0.2mM phenylmethylsulphonyl fluoride
(PMSF) and 0.83 mM benzamidine]. At the same time,
tumour material from the same location was fixed in 4%
formalin and paraffin embedded for histological examination
(Figure 1).
The cell suspension was filtered and centrifuged at 1000g
for 3 min. After resuspension of the cells, 54.7% Percoll
solution (density = 1.07) was carefully underlaid, and cent-
rifuged at 1000g for 15min. The interphase cell layer was
collected, and the cells were washed in phosphate-buffered
saline (PBS). After recording the wet weight of the final cell
pellet, the materials were frozen and stored at -80°C.
During final preparation of the samples, cells were broken
by repeated freezing and thawing, and nucleic acids were
degraded using DNAse/RNAse. After lyophilisation, the
material was solubilised using a sample buffer containing
urea, NP-40 and 3-[(3-Cholamidopropyl)dimethylammonio]-
l-propanesulphonate (Chaps). After extensive mixing, any
remaining insoluble material was removed by centrifugation.
Finally, the protein concentration of the sample was deter-
mined (Bradford, 1976), and samples were stored at -80°C
prior to isoelectric focusing (IEF).
Two-dimensionalpolyacrylamide gel electrophoresis
2-DE was performed according to previous descriptions
(Franzen et al., 1993; Okuzawa et al., 1994). Briefly, glass
tubes of 1.2 mm x 200 mm were used for IEF, and gels were
cast to a length of 180 mm. IEF tubes were prefocused at
200 V for 60 min. A sample corresponding to 30fg of prot-
ein was applied to each tube, and focused for 14.5 h at
800 V, and finally for 1.0 h at 1000 V using a Protein II cell
(Bio-Rad) and Model 1000/500 Power Supply (Bio-Rad).
After IEF, gels were extruded into equilibration buffer (pH
the middle
The fresh surface of the tumour is scraped
Formalin fixed and paraffin embedded
Histology
Cell suspension -O- 2-DE
Figure 1 Schematic illustration showing the main steps in the
preparation procedure. The fresh surface of a resected tumour is
scraped with a scalpel. The cell-rich material that attaches to the
scalpel is transferred to ice-cold cell culture medium containing
5% fetal calf serum and protease inhibitors. In the same location
where the tumour surface was scraped, a small piece of the
tumour is harvested for fixation in 4% formalin for histological
examination.
6.8) containing sodium dodecyl sulphate (SDS), dithiothreitol
(DDT) and glycerol, frozen on dry ice immediately, and
finally stored at - 80°C.
A linear 10%-13%T gradient SDS-polyacrylamide gel
(1.0 x 180 x 190 mm in size) was used in the second dimen-
sion. The IEF gels were sealed using agarose on top of the
slab gels, and electrophoresed overnight using 10 mA per gel
at + 10°C.
After protein fixation, proteins were visualised by silver
staining (Morrissey, 1981).
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Identification ofknown polypeptides
Identification of human polypeptides was possible through
comparison of the 2-DE patterns obtained and previously
published 2-DE maps (Bhattacharya et al., 1990; Ochs et al.,
1981; Garrels and Franza, 1989; Celis et al., 1992), or co-
electrophoresis of purified polypeptides and subcellular fract-
ions, as well as characterised samples from other labor-
atories.
Cellular extract of vimentin and vimentin-derived polypep-
tides, tropomyosins and cytokeratins from the cell lysate of
cell lines MDA-231 (human breast cancer), MCF-7 (human
breast cancer) and WI38 (human lung fibroblasts) were
prepared for the identification of each group of spots (Gard
et al., 1979; Paulin et al., 1980; Matsumura et al., 1983).
Proliferating cell nuclear antigen (PCNA) was identified by
immunoblotting (PC10 monoclonal antibody against PCNA)
using a semi-dry system (Multiphore, Pharmacia-LKB Bio-
technology AB) and ECL detection (Amersham).
Results
Histopathologicalfindings
The histopathological diagnoses of all cases investigated are
presented in Table I. In addition to the routine hist-
opathological diagnosis, two pathologists re-evaluated all
cases independently. In three cases of adenocarcinoma (L206,
L223 and LTI0) the degree of differentiation was not deter-
mined because the histopathological specimen was too small
to reflect the characteristics of the entire tumour.
Table I Materials
Adenocarcinoma
Well differentiated
adenocarcinoma
Moderately differentiated
adenocarcinoma
Poorly differentiated
adenocarcinoma
Unknown differentiation
Squamous cell carcinoma
Large-cell carcinoma
Adenosquamous cell carcinoma
Small-cell carcinoma
Oat cell type
Intermediate cell type
Carcinoid tumour
(21 cases)
L122, L128, L129, L127,
L201, L207, LT26, LT29,
LT35
LTOI, LT15, LT20
L214, LT13, LT17, LT18,
LT21, LT30
L206, L223, LT1O
(ten cases)
L105, L106, LT03, L212,
L216, L219, LT16, LTl9,
LT22, LT34
(five cases)
L121, L215, LT14, LT27,
LT32
(one case)
L107
(five cases)
LIlO
L123, L130, L109, L210
(three cases)
L205, LT12, LT24I 2-DE analysis of human lung cancer
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Figure 2 Overview of the 2-DE pattern of SCLC (case LI 10). A
number of identified spots are indicated. These included heat
shock protein (hsp) 90, hsp 73, j-tublin (bT), lamin B (lamB),
cytokeratins 8 and 18 (k8 and k18), actin (A), numatin/protein
B23 (B23), PCNA, PCNA 'satellite' (P-S), tropomyosins 4 and 5
(TM4 and TM5) and glutathione-S-transferase (pi) (GST). The
regions subjected to detailed analysis in this study are enclosed by
boxes.
Evaluation of2-DEgels
Figure 2 shows 2-DE patterns of SCLC (sample LI 10). The
region chosen for detailed analysis is marked by a square.
For reference, the 2-DE patterns of the human diploid
lung fibroblast cell line W138, normal peripheral lymphocytes
and a clinical sample of human breast cancer were used
(Figure 3).
In the region marked in Figure 3 16 spots were tentatively
judged as polypeptides associated with histopathological
features. These spots were called TEOI, TE02, TE03 (these
three spots were obviously detected in NSCLC samples),
TSO1, TS02, TS03, TS04 (these four spots were detected in
almost all samples of SCLC), TAO1, TA02, TA03, TA04,
TA05 (these five spots were detected in almost all samples of
AdC), TSqOl, TSqO2, TSqO3 and TSqO4 (these four spots
were detected mainly in samples of SCC). The localisation of
all these spots is shown in each gel (see Figure 5), and the
expression levels of these spots were classified as 'negative',
'low', 'intermediate' and 'high'.
The calculated molecular weight and isoelectric point of
each polypeptide are shown in Table II. The isoelectric point
was calculated using a number of internal markers (Bjellqvist
et al., 1994).
All spots, except some TSq polypeptides, were undetected
in the human lung fibroblast cell line WI38. Also, normal
peripheral lymphocytes did not express these polypeptides,
with the exception of TE02, TSqO2, TAO1, TA02 and TA05,
but their expression levels were very low (Figure 3).
Most of the breast cancers expressed TEOI, TE02, TA03
and TA05, but the other polypeptides were detected in few
breast cancer samples (Table II, Figure 3).
TSqOl-__|E1::quzC_~~~~~~~~~~TA03
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Figure 3 2-DE patterns of the human diploid lung fibroblasts (WI38), normal peripheral lymphocytes and a representative sample
of breast cancer that were used as references. O, Polypeptides associated with epithelial cells; A, polypeptides associated with
SCLC; 0, polypeptides associated with AdC; 0, polypeptides associated with SCC. The locations of the 16 polypeptides
associated with histopathological differentiation were shown in the right lower figure.2-DEanalysis of human lung cancer
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Figure 4 shows 2-DE findings of some representative cases
of each histological type of PLC, and the 2-DE patterns of
each histological type of PLC are summarised in Figure 5.
Comparison ofthe 2-DE.findings ofSCLC, carcinoid tumour
and NSCLC
Expression of TEO], TE02 and TE03 TEOl and TE02
polypeptides were expressed at intermediate or high level in
all cases of NSCLC. On the other hand, the intermediate cell
type of SCLC and carcinoid tumour expressed low or
intermediate levels of these two polypeptides, and they were
not detected in the oat cell type of SCLC, human diploid
lung fibroblasts (WI38) or normal peripheral lymphocytes.
Most NSCLC (87.1%) expressed TE03 even though the
expression level was relatively low. However, TE03 was not
detected in any SCLC or carcinoid tumour.
Expression of TSOJ, TS02, TS03 and TS04 These four
polypeptides were detected in at least five out of eight
neuroendocrine tumour samples (SCLC and carcinoid tum-
our). One of the TS polypeptides was detected in only a few
samples from NSCLC (LTO1, L214, L121, LT32 and L107).
a
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Figure 4 Comparison of 2-DE patterns of PLC in the region shown in Figure 2. (a) Representative 2-DE patterns of AdC (L122
and LT35, WD AdC; LT15 and LT20, MD AdC; LT18 and LT17, PD AdC). (b) Representative 2-DE patterns of SCC (L105,
L106 and LT03). (c) 2-DE pattern of AdSCC (L107). (d) Representative 2-DE patterns of LCC (L121, L215 and LT27). (e)
Representative 2-DE patterns of SCLC (LI 0, oat cell type; L123 and L109, intermediate cell type). (f) 2-DE patterns ofcarcinoid
tumour (L205, LT12 and LT24). O, Polypeptides associated with epithelial cells; A, polypeptides associated with SCLC; 0,
polypeptides associated with AdC; 0, polypeptides associated with SCC.
Table II Polypeptides [molecular weight(kDa)/pI] associated with the
histopathological differentiation of primary lung carcinoma
(a) Potential markers for epithelial cells
TEOI (31.0/5.52) TE02 (31.0/5.25)
TE03 (34.0/5.46)
(b) Potential markers for neuroendocrine cells
TSOI (29.5/5.08) TS02 (26.6/5.33)
TS03 (25.0/5.23) TS04 (24.2/5.20)
(c) Potential markers for adenocarcinoma of the lung
TAOI (35.0/5.45) TA02 (35.0/5.29)
TA03 (32.8/5.54) TA04 (30.0/5.72)
TA05 (29.8/5.67)
(d) Potential markers for squamous cell lung carcinoma
TSqOl (33.0/4.72) TSqO2 (32.7/4.69)
TSqO3 (32.0/4.67) TSqO4 (31.2/5.16)
Oat cell type SCLC (Li 10) expressed all four spots
(TSO1-TS04), but in the intermediate cell type of SCLC
some of these four polypeptides showed weak or undetect-
able expression levels.
In comparison with SCLC and carcinoid tumour the 2-DE
patterns were extremely similar in terms of TE and TS
expression. However, all samples of carcinoid tumour exp-
ressed TA03 polypeptide, which was not detected in any
SCLC sample. On the other hand, SCLC expressed PCNA
and PCNA 'satellite', which were not detected in any car-
cinoid tumours.
Comparison ofthe 2-DEpatterns ofadenocarcinoma and other
histological types ofprimary lung cancer
Both TAO1 and TA02 could be clearly detected in 20 samples
out of 21 AdC samples, one AdSCC sample and four sam-Table III Estimated expression rates ofpolypeptides in breast cancer
sample
Expression rates (%) (n = 23)
TEOI
TE02
TE03
TSO1
TS02
TS03
TS04
TAO1
TA02
TA03
TA04
TA05
TSqOl
TSqO2
TSqO3
TSqO4
100.0
91.3
39.1
31.8
0
0
15.0
22.7
4.3
95.5
8.7
72.7
4.3
4.3
8.7
0
Adenocarcinoma (n = 21)
TEO1
TE02
TE03
TSO1
TS02
TS03
TS04
TAO1
TA02
TA03
TA04
TA05
TSqOl1
TSqO2
TSqO3
TSqO r
20 40 60
I I
80 100(%)
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ples out of five LCC samples, even though LTO1, L214,
LT18, LT30 (MD or PD AdC sample), AdSCC and LCC
cases expressed low levels. In one PD AdC (LT17), TAOI
was undetectable and TA02 showed a low expression level.
On the other hand, no samples from SCC, SCLC and car-
cinoid tumour expressed these two polypeptides.
Thirteen out of 21 AdC samples, one AdSCC sample and
two out of five LCC samples expressed TA03, TA04 and
TA05 polypeptides. However, no SCLC, carcinoid tumours
or SCC except LT03 expressed these three polypeptides
simultaneously.
The intensity and rate of each TA polypeptide correspond
to the degree of AdC differentiation (Figure 6). In particular,
the expression level of TAOI and TA02 was related with the
degree of AdC-differentiation.
Comparison of2-DEpatterns ofsquamous cell carcinoma and
other histological types ofprimary lung cancer
TSqOl, TSqO2, TSqO3 and TSqO4 polypeptides were exp-
ressed in more than 60% of SCC and AdSCC samples and in
Squamous cell carcinoma (n = 10)
TEO1
TE02
TE03
TSO1
TS02
TS03
TS04
TA01
TA02
TA03
TA04
TA05
TSqO1
TSqO2
TSqO3
TSqO4
20 40 60 80 100(%)
Adenosquamous cell carcinoma (n = 1)
TEOI
TE02
TE03
TSO1
TS02
TS03
TS04
TAOI
TA02
TA03
TA04
TA05
TSqO1
TSqO2
TSqO3
TSqO4
20 40 60 80 100(%)
Small-cell carcinoma (n = 5)
TEOl
TE02
TE03
TSO1 r&111=11111A
TS02
TS03
TSO4
TAOI
TA02
TA03
TA04
TAOS
TSqO1
TSqO2
TSqO3
TSqO4
Large cell carcinoma (n = 5)
TE01
TE02
TE03
TS01
TS02
TS03
TS04
TA01
TA02
TA03
TA04
TAOS
TSqOl
TSqO2
TSqO3
TSqO4
Carcinoid (n= 3)
TE01
TE02
TE03
TS01
TSO2
TS03
TS04
TAO1
TA02
TA03
TA04
TA05
TSqOl
TSqO2
TSqO3
TSqO4
20 40 60 80 100(%)
20 40 60 80 100(%)
Figure 5 The relationship between histopathology and 16
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Well-differentiated adenocarcinoma (n = 9)
TAO1
TA02
TA03
TA04
TA05
Moderately differentiatied adenocarcinoma (n =3)
TA01
TA02
TA03
TA04
TA05
_~~~~~~~
I _
Poorly differentiated adenocarcinoma (n = 6)
TAO1
TA02
TA03
TA04
TA05
I~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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Figure 6 The relationship between the differentiation to AdC
and 16 unidentified polypeptides. , high expression level.
1M, intermediate expression level. LII, low expression level.
fewer than 20% of AdC samples. These four TSq polypep-
tides seem to be associated with SCC.
Discussion
Primary lung cancer (PLC) is one of the most malignant
solid tumours, and lung cancer incidence and thus mortality
is increasing. Clinically, lung cancer is divided into SCLC
and NSCLC. This division guides the therapeutic strategy
because of the large difference in the sensitivity to chemo-
therapy as well as radiotherapy, and in the frequency of
distant metastasis. Usually, it is possible to distinguish
between SCLC and NSCLC on the basis of morphology.
However, recently it has been shown that cases borderline
between SCLC and NSCLC exist, causing diagnostic
difficulties.
Gazdar et al. (1988) showed that at least 10% of NSCLC
are accompanied by neuroendocrine features (NE) (e.g. L-
dopa decarboxylase and chromogranin A) and that these
tumours possess cytoplasmic granules resembling neuro-
endocrine granules. Also, NSCLC with NE is more sensitive
to chemotherapy than typical NSCLC which do not show
NE. However, it has been reported to be impossible to
distinguish histologically between typical NSCLC and
NSCLC with NE (Gazdar and Linnoila, 1988). Furthermore,
it has been shown that a few cases of AdC of the lung
express cluster 1 SCLC antigen (Tome et al., 1991), which is
present on every SCLC, as well as on neural, endocrine and
muscle cells (Hirano et al., 1989). At present, this antigen is
considered to be synonymous with the neural cell adhesion
molecule (N-CAM) (Patel et al., 1989).
It is known that approximately 5% of SCLC have a
component of SCC or AdC (combined small-cell type) (Hirsh
et al., 1988). In fact, SCLC expresses characteristics of both
neuroendocrine cells and epithelial cells. In oat cell type
SCLC, the neuroendocrine character dominates, whereas the
epithelial character is predominant in the intermediate cell
type SCLC. In this context, it has been reported that some
SCLC cases which do not possess cytoplasmic granules
resembling neuroendocrine granule show a more epithelial
character, and this subtype of SCLC may be less sensitive to
radiotherapy or chemotherapy than oat cell carcinoma. This
kind of SCLC is called SCLC with a large-cell component or
undifferentiated carcinoma of SCLC type (Radice et al.,
1982; Nomori et al., 1986; Hirsh et al., 1988).
All these findings show that borderline cases between
SCLC and NSCLC exist, and it is very difficult to distinguish
these cases from either typical SCLC or NSCLC based only
on morphological findings. Therefore, it is valuable to
analyse the gene expression of PLC, and we consider that the
analysis of polypeptides associated with PLC, using 2-DE,
may reflect the biological characteristics of the tumour more
accurately.
Potential markersfor epithelial cells
TEOl and TE02 were strongly expressed in all NSCLC.
However, these two polypeptides were not detected in all
cases of oat cell carcinoma (L11O case), while intermediate
cell type SCLC expressed low levels compared with NSCLC.
These polypeptides were also detected in all breast cancer
samples analysed (Table III). In some samples of cultured
cells of lung AdC and breast cancer, we could detect a
tendency for the expression level to decrease as compared
with clinical material (data not shown).
Although the level and rate of expression of TE03 were
low even in NSCLC, no carcinoid tumours and only one
SCLC sample (L123, intermediate cell type of SCLC) exp-
ressed TE03 at all. The present results suggest that these
three polypeptides originated from epithelial cells. Sample
L109 showed the highest intensity of TEOl and TE02 of the
intermediate cell type SCLC. Nomori et al. (1986) designated
undifferentiated carcinoma of the small-cell type (USC) as a
subtype of SCLC. In this type of SCLC some neuroendocrine
markers are negative and some epithelial markers are positive
immunohistochemically. The biological characteristics of
L109 may resemble those of USC.
We believe that these three TE polypeptides may be
valuable not only to distinguish between SCLC and NSCLC,
but also to guide the therapeutic strategy of SCLC by
evaluating the epithelial characteristics of SCLC. This is
because an increase in the epithelial characteristics may result
in a lower sensitivity to chemotherapy.
Potential markersfor neuroendocrine cells
The findings concerning the histological distribution of TSO1,
TS02, TS03 and TS04 suggest that these four polypeptides
originate from neuroendocrine cells. Expression of these four
polypeptides in oat cell type SCLC (L110) supports the
concept that these polypeptides may reflect neuroendocrine
features (NE). Even in intermediate cell type SCLC and
carcinoid tumours in which low levels of TEOl and TE02 are
detected, more than two polypeptides out of these four TS
polypeptides are expressed.
Neuron cytoplasmic protein has a molecular weight of
26.3 kDa and pl 5.44 (Celis et al., 1992), and may corres-
pond to either TS02 or TS03.
Although no NSCLC samples expressed more than two
kinds of TS polypeptides, samples LOlT (PD AdC), L121,
LT32 (LCC) and L107 (AdSCC) expressed one of these TS
polypeptides. These four cases showed positive staining of
neuron-specific enolase, and in one of these four cases
chromogranin A was detected. Furthermore, the tumour with
chromogranin A positive staining possessed cytoplasmic
granules resembling neuroendocrine granules (data not
shown). These findings suggested that some of the four
tumours that expressed one TS polypeptide might be NSCLC
with NE, and that TS polypeptides might be associated with
NE. However, in order to confirm the relationship between
these four polypeptides and NE, more data are necessary.
Potential markers ofadenocarcinoma ofthe lung
TAO1 and TA02 showed some of the highest intensities
among all spots in 2-DE gels of bronchioloalveolar cell carc-
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inoma (samples L122, LT26 and LT35). In addition, six cases
with the highest expression of TAOl and TA02 were diag-
nosed as WD AdC. Four out of five samples which showed
weak expression of these two polypeptides were diagnosed as
PD AdC. Therefore, we concluded that there is a strong
relationship between the expression level of these two
polypeptides and the differentiation of AdC.
On the other hand, only five out of 23 breast cancer
samples expressed TAO1, and one of these breast cancer
samples expressed a low level of TA02 (Table III). Further-
more, three cases of metastatic lung carcinoma from the
colon and rectum did not express these two polypeptides
(data not shown). These findings suggest that these two
polypeptides may have some specificity for AdC of the lung.
Antibodies against TAOI and TA02 are needed to investigate
the detailed cellular distribution of these polypeptides.
The expression of TA04 was low in AdC cases, but it was
hardly ever detected in SCLC, SCC, breast cancer or metast-
atic lung cancer from the colon and rectum. In addition to
TAOI and TA02, TA04 may be useful to distinguish between
primary AdC and metastatic AdC from other organs.
In comparison with the findings for TAOI, TA02 and
TA04, the range of distribution of TA03 and TA05 was
rather wide, because most breast cancers expressed TA03 and
TA05. It is highly possible that TA03 and TA05 may be
common polypeptides in adenocarcinomas.
Potential markersfor squamous cell lung carcinoma
It is difficult to define the polypeptides associated with SCC.
Necrotic tissue is often observed in SCC, and bacterial infec-
tion is sometimes present. Therefore, it is very difficult to
analyse SCC. In this study candidates for SCC-associated
polypeptides are described. However, although AdC, SCLC
and carcinoid tumours expressed some of these polypeptides,
the number and level of expression of SCC-associated
polypeptides are low.
Analysis ofadenosquamous cell carcinoma and large-cell
carcinoma
The AdSCC sample (L107) expressed all polypeptides
associated with both AdC and SCC as well as three TE
polypeptides. The level of expression of TE polypeptides was
high or intermediate, but the other polypeptides associated
with AdC and SCC were expressed relatively weakly. These
findings in AdSCC seem to be reasonable, because each
polypeptide may be diluted by the polypeptides associated
with other histological entities.
Similar findings were observed in the 2-DE pattern of four
out of five LCC cases. We believe that LCC cells have a
weak potential to differentiate to both AdC and SCC, which
is subsequently reflected by the mixed type of the 2-DE
pattern. The fact that the 2-DE pattern of PD AdC shows
low levels of TA polypeptides and little expression of TSq
polypeptides supports this hypothesis (Figure 6).
We have previously identified several kinds ofpolypeptides
associated with high proliferation (e.g. PCNA, PCNA 'satel-
lite', numatin/protein B23 and lamin B). We also reported
that the high levels of PCNA, B23 and lamin B, and the
expression of PCNA 'satellite' may indicate rapidly growing
tumours (Okuzawa et al., 1994). These polypeptides were
frequently detected in SCLC. In this study in which we
analysed polypeptides mainly in the molecular weight region
20-35 kDa of 2-DE gel, we could not establish any definite
difference between SCLC and carcinoid tumours. However,
by comparing the polypeptides associated with high prolifera-
tion it is possible to distinguish SCLC from carcinoid
tumours in 2-DE findings. It is valuable to analyse several
kinds of differentiation markers and proliferation markers
simultaneously. We believe that the combination of 2-DE
and the non-enzymatic sample preparation technique enables
the simultaneous evaluation of these markers in clinical
material.
We observed that the major fraction of resolved polypep-
tides varies significantly among the cases. However, small
differences in 2-DE patterns between parallel samples from
the same tumour were detected, because clinical samples
always show tumour heterogeneity and contamination by
non-tumour cells (e.g. fibroblasts, lymphocytes and
granulocytes) (Franzen et al., 1993). In the present study it is
important to compare the results of the clinical samples with
the 2-DE pattern from fibroblasts and lymphocytes. Even
though fibroblasts or lymphocytes expressed some of these
polypeptides, the level of expression of most of the polypep-
tides was much lower than the level found in cancerous
samples. No relationship between the intensity of the
histology-associated polypeptides and the number of mesen-
chymal cells and lymphocytes was observed in this study.
The ultimate aim of this study was to characterise the
various histologically defined tumours by means of specific
2-DE patterns. It is reasonable to assume that there are
relationships betwen biological characteristics, sensitivity to
several kinds of therapy and prognosis. For that purpose,
investigation of the relationship between the polypeptides
associated with the histopathological differentiation of PLC
and both neuroendocrine characteristics and epithelial
characteristics may be an effective strategy.
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